Page 10 - Flipbook

Cisplatin-Ineligiblity

• Method of determining kidney function is variable

• Non-cisplatin-based options inferior

st
‒ 1 -line cisplatin-based chemo 1,2 ‒ 1 -line carboplatin-based chemo 3
st
▪ ORR 50% ▪ ORR 36%

▪ Median PFS 7.7 months ▪ Median PFS 5.8 months

▪ Median OS 15 months ▪ Median OS 9 months

▪ 1 year OS 60% ▪ 1 year OS 37%

• Novel immunotherapy approaches show promise

1. von der Maase H, et al. J Clin Oncol. 2000;18(17):3068-77.
2. von der Maase H, et al. J Clin Oncol . 2005;23(21):4602-8.
3. De Santis M, et al. J Clin Oncol. 2012;30(2):191-9.